Taribavirin
目录号 : GC37740
Taribavirin 是一种肌苷一磷酸脱氢酶抑制剂，具有抗多种病毒的活性，特别是丙型肝炎病毒和流感病毒。Taribavirin 是一种利巴韦林前药，旨在集中在肝脏内以靶向 HCV 感染的肝细胞，同时最小化红细胞 (RBC) 内的分布和溶血性贫血的发展。
Cas No.:119567-79-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Taribavirin is an inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus[1].Taribavirin, is a ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia[2].
Taribavirin (0-2 μM; 24 hours) significantly induces MCF-7 cell death, recording half inhibitory effect (IC50) of 0.756 μM in MCF-7 cells[1]. Cell Viability Assay[1] Cell Line: MCF-7 cells
[1]. Abd-Rabou AA, et al. Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer. Pharm Res. 2018 Feb 27;35(4):76. [2]. Deming P, et al. Taribavirin in the treatment of hepatitis C. Expert Opin Investig Drugs. 2011 Oct;20(10):1435-43.
| Cas No. | 119567-79-2 | SDF | |
| Canonical SMILES | N=C(C1=NN([C@H]2[C@@H]([C@@H]([C@@H](CO)O2)O)O)C=N1)N | ||
| 分子式 | C8H13N5O4 | 分子量 | 243.22 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.1115 mL | 20.5575 mL | 41.115 mL |
| 5 mM | 0.8223 mL | 4.1115 mL | 8.223 mL |
| 10 mM | 0.4112 mL | 2.0558 mL | 4.1115 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Taribavirin in the treatment of hepatitis C
Expert Opin Investig Drugs 2011 Oct;20(10):1435-43.PMID:21854301DOI:10.1517/13543784.2011.606214.
Introduction: Treatment of chronic hepatitis C virus (HCV) is limited by substantial side effects including ribavirin-induced hemolytic anemia. Taribavirin, a ribavirin prodrug, was designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the subsequent development of hemolytic anemia. Areas covered: The objective of the review is to evaluate the efficacy and safety of Taribavirin as compared with ribavirin in the treatment of chronic HCV infections. A PubMed search was performed using the following key words: viramidine, Taribavirin and ribavirin analog. Additional sources included press releases on preliminary results of clinical trials of Taribavirin and abstracts presented at international meetings. The literature suggests that weight-based dosing of Taribavirin at 25 mg/kg demonstrates lower rates of hemolytic anemia with comparable rates of sustained virologic response (SVR) and is the optimum dose for further studies comparing the efficacy of Taribavirin with weight-based dosing of ribavirin. Expert opinion: Failure to eradicate HCV may be associated with extrahepatic viral replication. The dosing strategy of Taribavirin favors concentration within the liver to reduce treatment-limiting rates of anemia but may be insufficient to prevent virologic relapse.
Taribavirin for the treatment of chronic hepatitis C
Expert Opin Pharmacother 2008 Dec;9(18):3243-9.PMID:19040344DOI:10.1517/14656560802594459.
Background: The current standard therapy for chronic hepatitis C virus (HCV), combination therapy with pegylated interferon and ribavirin, is plagued by a number of side effects, most notably anemia. This anemia is typically managed with a reduction of ribavirin dosing, which may lead to reduced efficacy. Taribavirin, an oral prodrug of ribavirin, which has been shown to induce a lesser degree of anemia, is being investigated for the treatment of chronic HCV. Objective: To summarize the clinical trials involving Taribavirin and its potential role in the treatment of chronic HCV. Methods: Information was obtained via searches for data related to Taribavirin, as well as other current and investigational therapies for chronic HCV. Press releases discussing otherwise unpublished trial outcomes were obtained from the website of Valeant Pharmaceuticals, the producer of Viramidine (Taribavirin). Conclusion: Taribavirin may increase adherence to therapy for chronic HCV by reducing the need for dose reduction due to anemia. A recent Phase II trial investigating early and sustained virological response showed no statistically significant differences between ribavirin 1000/1200 mg and Taribavirin at 800-, 1200-, or 1600-mg dosing, while illustrating a lesser degree of anemia in 800- and 1200-mg dosing of Taribavirin. Ongoing studies will continue to examine the efficacy of combination therapy with Taribavirin in the place of ribavirin.
Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer
Pharm Res 2018 Feb 27;35(4):76.PMID:29488022DOI:10.1007/s11095-017-2283-3.
Purpose: Breast cancer is the second most common cause of mortality in women in the United States. Targeted delivery of antitumor breast cancer drugs as a drug-delivery strategy may allow direct delivery into the tumor. Currently, chemotherapy is one of the principle strategies for cancer treatment, but it can have toxic side effects. Nanotechnology attempts to resolve these challenges by loading drugs in nanoparticles, such as solid lipid nanoparticles (SLN). In response to the breast cancer drug 5-fluorouracil (5-FU), p38MAPK signaling has been investigated since the 1990s. Ribavirin, a nucleotide derivative, inhibits p38MAPK in infected hepatocytes. A ribavirin prodrug, Taribavirin (TBV), was recently synthesized to concentrate in the liver and have minimal concentration in red blood cells. Methods: In this study, TBV and 5-FU-pegylated SLNs were prepared and characterized. The in vitro cytotoxicity was evaluated against MCF-7 breast cancer cells. Using molecular docking experiments, 5-FU and TBV were docked on p38MAPK protein. Results: The TBV nanoformulation had the highest cytotoxic effects, achieving IC50 = 0.690 μM after 24 h, compared with free TBV, which also achieved a good cytotoxic effect (IC50 = 0.756 μM). However, there was a detectable cytotoxic effect and an undetectable IC50 of 5-FU nanoparticles and free 5-FU on MCF-7 cells. Conclusions: The effect of TBV nanoparticles on MCF-7 cells may be due to its inhibitory effect against p38MAPK protein, where it fits inside the active pocket site of the p38 protein molecular surface, with a minimum binding affinity of -5.5 kcal/mol (rmsd of 1.07), and it formed strong hydrogen bonds with amino acids ASP'168, ILE'166, HIS'148, and ILE'147. Further studies are warranted to investigate the mechanistic details of the proposed approach.
Ribavirin analogs
Clin Liver Dis 2009 Aug;13(3):419-27.PMID:19628158DOI:10.1016/j.cld.2009.05.006.
Ribavirin is ineffective against hepatitis C virus as mono-therapy but is critical in attaining both early virologic response and sustained virologic response when combined with pegylated interferon. Ribavirin has significant dose-limiting toxicities, the most important of which is hemolytic anemia. Taribavirin is a ribavirin pro-drug, which targets the liver and has less incidence of anemia, and it may be a promising alternative to ribavirin in the future.
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with Taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study
J Hepatol 2007 Jul;47(1):51-9.PMID:17470380DOI:10.1016/j.jhep.2007.02.018.
Background/aims: Pegylated interferon plus ribavirin can cause dose-limiting anemia. Taribavirin, a ribavirin prodrug, has shown a lower incidence of anemia. We sought to determine the efficacy and safety of Taribavirin vs. ribavirin combined with pegylated interferon in patients with chronic hepatitis C (CHC). Methods: This phase 2 open-label study randomized 180 patients with CHC to receive pegylated interferon alfa-2a 180 microg/week plus Taribavirin 800, 1200 or 1600 mg QD or ribavirin 1000 or 1200 mg QD. Efficacy variables included proportions of patients with undetectable serum HCV RNA levels at end of treatment and after a 24-week follow-up. Results: The proportions of patients with undetectable HCV RNA at 12 weeks did not differ significantly between Taribavirin (38%, 42%, and 49% for the 800, 1200, and 1600 mg groups) and ribavirin (49%). The highest proportion of patients with undetectable HCV RNA at end of treatment and at follow-up occurred in both the Taribavirin 1200mg QD (63% and 37%) and ribavirin groups (62% and 44%). SVR rates were 23%, 37% and 29% for Taribavirin and 44% for ribavirin. Fewer patients on any dose of Taribavirin had severe anemia (hemoglobin <10 g/dL) than on ribavirin (6/135 [4%] vs. 12/45 [27%]). Conclusions: Given with interferon, Taribavirin produced SVR rates comparable to those of ribavirin, with a lower occurrence of anemia.